Germany’s coalition government has retreated further on its controversial medical cannabis reimbursement reforms as it faces mounting questions over how and why the law came to be.
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to VER-01, the flagship full-spectrum cannabis drug from Munich-based Vertanical, putting it in prime position to become the first FDA-approved cannabis-derived medicine for pain, and only the second such approval since Epidiolex in 2018.
Findings from the successful trials of a new, multi-compound, cannabis medicine look set to deliver a major breakthrough for the world’s half-a-billion chronic low back pain (CLB) sufferers.
